Chidamide augment sorafenib-derived anti-tumor activities in human osteosarcoma cells lines and xenograft mouse model-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Chidamide augment sorafenib-derived anti-tumor activities in human osteosarcoma cells lines and xenograft mouse model

Published:2022-04-28 Issue:6 Volume:39 Page:
ISSN:1559-131X
Container-title:Medical Oncology
language:en
Short-container-title:Med Oncol

Author:

Yuan Ying,Li Daifeng,Hu Xiang,Li Yizhou,Yi Wanrong,Li Pengcheng,Zhao Yong,Li Zonghuan,Yu Aiming,Jian Chao,Yu Aixi^ORCID

Funder

Hubei Province Scientific and Technical Innovation Key Project

Hubei Province Medical Leading Talent Project

Medical Science and Innovation Platform Supporting Project of Health Commission of Hubei Province

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s12032-022-01684-1.pdf

Reference45 articles.

1. Ma O, Cai WW, Zender L, et al. MMP13, Birc2 (cIAP1), and Birc3 (cIAP2), amplified on chromosome 9, collaborate with p53 deficiency in mouse osteosarcoma progression. Cancer Res. 2009;69(6):2559–67. https://doi.org/10.1158/0008-5472.CAN-08-2929.

2. Gill J, Gorlick R. Advancing therapy for osteosarcoma. Nat Rev Clin Oncol. 2021;18(10):609–24. https://doi.org/10.1038/s41571-021-00519-8.

3. Savage SA, Mirabello L. Bone cancer: Is the osteosarcoma genome targetable? Nat Rev Endocrinol. 2017;13(9):506–8. https://doi.org/10.1038/nrendo.2017.101.

4. Luetke A, Meyers PA, Lewis I, et al. Osteosarcoma treatment—where do we stand? A state of the art review. Cancer Treat Rev. 2014;40(4):523–32. https://doi.org/10.1016/j.ctrv.2013.11.006.

5. Isakoff MS, Bielack SS, Meltzer P, et al. Osteosarcoma: current treatment and a collaborative pathway to success. J Clin Oncol. 2015;33(27):3029–35. https://doi.org/10.1200/JCO.2014.59.4895.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3